Showing results (31-40 of 49) with videos related to
Sort By:
Pageof 5
Journal of Medicinal Chemistry|November 6, 2012
P2-substituted N-acylprolylpyrrolidine inhibitors of prolyl oligopeptidase: biochemical evaluation, binding mode determination, and assessment in a cellular model of synucleinopathyPieter Van der Veken, Vilmos Fülöp, Dean Rea, et al.Seminars in Oncology|January 10, 2006
Can molecular imaging predict response to preoperative chemoradiation in patients with rectal cancer? A Fox Chase Cancer Center prospective experienceAndre Konski, John Hoffman, Elin Sigurdson, et al.The Lancet. Oncology|June 2, 2016
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trialTanguy Y Seiwert, Barbara Burtness, Ranee Mehra, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2016
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 StudyRita Nanda, Laura Q M Chow, E Claire Dees, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2004
Individualized patient dosing in phase I clinical trials: the role of escalation with overdose control in PNU-214936Jonathan D Cheng, James S Babb, Corey Langer, et al.International Journal of Radiation Oncology, Biology, Physics|May 29, 2007
Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinomaAndre A Konski, Jonathan D Cheng, Melvyn Goldberg, et al.American Journal of Clinical Oncology|May 12, 2010
Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinomaIgor A Astsaturov, Neal J Meropol, R Katherine Alpaugh, et al.Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 12, 2012
Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancerAndre Konski, Tianyu Li, Michael Christensen, et al.Clinical Colorectal Cancer|February 12, 2014
A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancersCrystal S Denlinger, Neal J Meropol, Tianyu Li, et al.Cancer Biology & Therapy|November 23, 2007
Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancerKalyani Narra, Stefanie R Mullins, Hyung-Ok Lee, et al.Pageof 5